Tech Company Financing Transactions
PAQ Therapeutics Funding Round
PAQ Therapeutics secured a $39 million Series B venture capital round on 5/7/2025. Backers included Bayland Capital, BioTrack Capital and Johnson & Johnson Innovation.
Transaction Overview
Company Name
Announced On
5/7/2025
Transaction Type
Venture Equity
Amount
$39,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the next stage of clinical development for its lead asset PT0253.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
625 Mass Ave. 02-146
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
PAQ's platform is driven by autophagosome-tethering compounds (ATTECs), small molecules with the potential to catalyze and selectively enhance the degradation of disease-causing entities through autophagy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nan Ji
Co-Founder
Huaixiang Hao
Browse more venture capital transactions:
Prev: 5/7/2025: FirmPilot venture capital transaction
Next: 5/7/2025: NewLimit venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs